治疗阿尔茨海默病新药盐酸美金刚  

Memantine:a new drug for Alzheimer's disease

作　　者：罗京京[1] 何玲[1] 刘国卿[1] 

机构地区：[1]中国药科大学药理教研室,南京210009

出　　处：《中国新药杂志》2006年第9期742-744,共3页Chinese Journal of New Drugs

基　　金：江苏省自然科学基金(BK2004110)

摘　　要：N-甲基-D-天门冬氨酸(NMDA)受体阻滞剂盐酸美金刚是FDA批准的第1个用于治疗中、重度阿尔茨海默病(Alzheimer's disease,AD)的药物,主要通过调节脑内谷氨酸水平发挥作用。临床研究表明,盐酸美金刚是一种安全、有效,且较有市场前景的药物,单用或与多奈哌齐联用都有明显的治疗作用;口服20 mg·d^(-1)对中、重度AD患者的认知、行为能力等方面都有明显改善。Memantine, the first and only representative of a new class of Alzheimer drug-a moderate affinity NMDA-receptor antagonist, was approved for treatment of moderate to severe Alzheimer＇s disease in Europe and US. Memantine appears to protect the brain＇s nerve cells against glutamate, a messenger chemical released in excess amounts by cells damaged by Alzheimer＇s disease or certain other neurological disorders. Clinically, monotherapy or combination of memantine with donepezil shows significant improvements of cognition and action abilities in patients with moderate or severe AD. AD patients are evident to get huge benefits in the treatment of memantine.

关 键 词：盐酸美金刚 阿尔茨海默病 NMDA受体阻滞剂 学习记忆 

分 类 号：R971.5[医药卫生—药品]